Sponsor content
74 result(s) found, displaying 1 to 10
-
Prescription medicine decision summaryAflivu and Ahzantive (aflibercept) are approved for wet age-related macular degeneration, macular oedema secondary to central retinal vein occlusion and branch retinal vein occlusion, diabetic macular oedema, and myopic choroidal neovascularisation.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AFLIVU aflibercept (rch) 40 mg/mL solution for intravitreal injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AFLIVU aflibercept (rch) 40 mg/mL solution for intravitreal injection vial.
-
AHZANTIVE aflibercept (rch) 40 mg/mL solution for intravitreal injection pre-filled syringe (489561)
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AHZANTIVE aflibercept (rch) 40 mg/mL solution for intravitreal injection pre-filled syringe. -
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AHZANTIVE aflibercept (rch) 40 mg/mL solution for intravitreal injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for APIXABAN ACTOR apixaban 1.25 mg/1 mL oral liquid suspension bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AXORAN apixaban 1.25 mg/1 mL oral liquid suspension bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for APIXABAN ACPH apixaban 1.25 mg/1 mL oral liquid suspension bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ACTARIN midostaurin 25 mg soft capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MIDOSTAURIN ACTOR midostaurin 25 mg soft capsule blister pack.